2024
Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalencePredictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records
Ryuk D, Pelissari D, Alves K, Oliveira P, Castro M, Cohen T, Sanchez M, Menzies N. Predictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records. BMC Infectious Diseases 2024, 24: 531. PMID: 38802744, PMCID: PMC11129366, DOI: 10.1186/s12879-024-09417-7.Peer-Reviewed Original ResearchConceptsTreatment outcomesFactors associated with unsuccessful treatment outcomesHigher risk of poor treatment outcomeTB treatmentRisk of poor treatment outcomesUnsuccessful treatmentEffectiveness of TB treatmentAssociated with unsuccessful treatmentUnsuccessful treatment outcomesTuberculosis treatment outcomesDrug-susceptible TBHealth system levelMultivariate logistic regression modelService-related factorsTB drug resistanceComorbid health conditionsHealth-related behaviorsCategorizing treatment outcomesPatient-level factorsClinical examination resultsNational Disease Notification SystemPoor treatment outcomesDisease notification systemHIV infectionLogistic regression modelsImpact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-RRacial and ethnic disparities in diagnosis and treatment outcomes among US-born people diagnosed with tuberculosis, 2003–19: an analysis of national surveillance data
Regan M, Li Y, Swartwood N, Barham T, Asay G, Cohen T, Hill A, Horsburgh C, Khan A, Marks S, Myles R, Salomon J, Self J, Menzies N. Racial and ethnic disparities in diagnosis and treatment outcomes among US-born people diagnosed with tuberculosis, 2003–19: an analysis of national surveillance data. The Lancet Public Health 2024, 9: e47-e56. PMID: 38176842, DOI: 10.1016/s2468-2667(23)00276-1.Peer-Reviewed Original ResearchConceptsNational surveillance dataNon-Hispanic White peopleTreatment outcomesEthnic disparitiesSurveillance dataTuberculosis diagnosisUS National Tuberculosis Surveillance SystemIndex of disparityLog-binomial regression modelsNational Tuberculosis Surveillance SystemNon-Hispanic black peopleOverall high riskTuberculosis Surveillance SystemAlaska Native peopleTuberculosis patientsDiagnostic delayAdverse outcomesTuberculosis diseaseTuberculosis incidence
2023
Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis
Menzies N, Allwood B, Dean A, Dodd P, Houben R, James L, Knight G, Meghji J, Nguyen L, Rachow A, Schumacher S, Mirzayev F, Cohen T. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nature Communications 2023, 14: 6182. PMID: 37794037, PMCID: PMC10550952, DOI: 10.1038/s41467-023-41937-9.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsRifampicin-resistant tuberculosisRR-TBGlobal burdenSubstantial short-term morbidityRifampicin-susceptible tuberculosisShort-term morbidityOverall disease burdenLong-term health impactsPost-treatment careTB survivorsDisease burdenTreatment outcomesTuberculosis survivorsCase detectionLife yearsRifampicin resistanceTuberculosisHealth impactsBurdenHealth expenditureDiseaseSurvivorsMathematical modeling analysisFormer Soviet Union countries
2022
A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates
Fowler P, Wright C, Spiers H, Zhu T, Baeten E, Hoosdally S, Cruz A, Roohi A, Kouchaki S, Walker T, Peto T, Miller G, Lintott C, Clifton D, Crook D, Walker A, Barilar I, Battaglia S, Borroni E, Brandao A, Brankin A, Cabibbe A, Carter J, Cirillo D, Claxton P, Clifton D, Cohen T, Coronel J, Crook D, Earle S, Escuyer V, Ferrazoli L, Fowler P, Gao G, Gardy J, Gharbia S, Ghisi K, Ghodousi A, Cruz A, Grazian C, Guthrie J, He W, Hoffmann H, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Jarrett L, Joseph L, Jou R, Kambli P, Knaggs J, Koch A, Kohlerschmidt D, Kouchaki S, Lachapelle A, Lalvani A, Lapierre S, Laurenson I, Letcher B, Lin W, Liu C, Liu D, Malone K, Mandal A, Matias D, Meintjes G, Mendes F, Merker M, Mihalic M, Millard J, Miotto P, Mistry N, Moore D, Dreyer V, Chetty D, Musser K, Ngcamu D, Nhung H, Grandjean L, Nilgiriwala K, Nimmo C, Okozi N, Oliveira R, Omar S, Paton N, Peto T, Pinhata J, Plesnik S, Puyen Z, Rabodoarivelo M, Rakotosamimanana N, Rancoita P, Rathod P, Robinson E, Rodger G, Rodrigues C, Rodwell T, Roohi A, Santos-Lazaro D, Shah S, Kohl T, Smith G, Solano W, Spitaleri A, Supply P, Steyn A, Surve U, Tahseen S, Thuong N, Thwaites G, Todt K, Trovato A, Utpatel C, Van Rie A, Vijay S, Walker T, Walker A, Warren R, Werngren J, Groenheit R, Wijkander M, Wilkinson R, Wilson D, Wintringer P, Xiao Y, Yang Y, Yanlin Z, Yao S, Zhu B, Niemann S, O'Donnell M. A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates. ELife 2022, 11: e75046. PMID: 35588296, PMCID: PMC9286738, DOI: 10.7554/elife.75046.Peer-Reviewed Original ResearchConceptsMinimum inhibitory concentrationIncreasing prevalence of resistanceBroth microdilution platesAntibiotic susceptibility testingPrevalence of resistanceInhibitory concentrationPanel of antibioticsClinical samplesSusceptibility testingMicrodilution platesDilution platingTreatment outcomesIncreased prevalenceAntitubercular drugsAntibioticsInhibited growthDrugCitizen science platformRespiratory diseaseLaboratory scientistsVolunteersPre-determined concentrations
2018
Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings
Cudahy PGT, Andrews JR, Bilinski A, Dowdy DW, Mathema B, Menzies NA, Salomon JA, Shrestha S, Cohen T. Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. The Lancet Infectious Diseases 2018, 19: e89-e95. PMID: 30554997, PMCID: PMC6401264, DOI: 10.1016/s1473-3099(18)30443-2.Peer-Reviewed Original ResearchConceptsTuberculosis incidenceLow tuberculosis incidence settingsActive case-finding strategyHigh tuberculosis (TB) incidence countriesCase-finding strategyTuberculosis control strategiesHigh-incidence settingsInfectious causesIncidence settingsIncidence countriesTuberculosis transmissionTreatment outcomesActive screeningOnward transmissionSystematic reviewInfectious individualsInfectious periodTuberculosisIncidenceDeathCauseProximal causeHIVMixed resultsMortalityTrends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogenTuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study
Marx FM, Yaesoubi R, Menzies NA, Salomon JA, Bilinski A, Beyers N, Cohen T. Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. The Lancet Global Health 2018, 6: e426-e435. PMID: 29472018, PMCID: PMC5849574, DOI: 10.1016/s2214-109x(18)30022-6.Peer-Reviewed Original ResearchConceptsHigh-incidence settingsIsoniazid preventive therapyPreventive therapyTuberculosis treatmentActive casesHIV prevalenceTuberculosis controlControl interventionsIncident tuberculosis casesPrevious tuberculosis treatmentTuberculosis control interventionsTB case notificationHigh-risk groupTransmission dynamic modelTuberculosis deathsHigh tuberculosisRecurrent diseasePrevalent tuberculosisTuberculosis casesTuberculosis incidenceCase notificationTreatment outcomesTuberculosis morbidityTuberculosis epidemicAdditional interventions
2016
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective
Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal Of Infectious Diseases 2016, 56: 185-189. PMID: 28007660, PMCID: PMC5576040, DOI: 10.1016/j.ijid.2016.12.010.Peer-Reviewed Original ResearchConceptsSecond-line drug susceptibility testingRifampin-resistant tuberculosisDrug susceptibility testingSecond-line drug resistanceDrug resistanceSusceptibility testingHigh-burden settingsSecond-line drugsDrug-resistant tuberculosisEffective regimensTreatment failureTreatment outcomesSmall incremental costEpidemiologic benefitsResistance amplificationPatientsTuberculosisIncremental costMost settingsWidespread implementationSettingRegimensPrevalenceRapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study
Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, Wiggins K, Gillece JD, Schupp JM, Catanzaro DG, Crudu V, Cohen T, Rodwell TC, Engelthaler DM. Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. Journal Of Clinical Microbiology 2016, 54: 2058-2067. PMID: 27225403, PMCID: PMC4963505, DOI: 10.1128/jcm.00535-16.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGenotyping TechniquesHigh-Throughput Nucleotide SequencingHumansMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPharmaceutical PreparationsPilot ProjectsSequence Analysis, DNASpecimen HandlingSputumTime FactorsYoung AdultConceptsDrug-resistant tuberculosisPatient sputum samplesDrug resistance profilesSputum samplesDrug-resistant Mycobacterium tuberculosis isolatesPhenotypic drug susceptibility testing resultsDrug susceptibility testing resultsEvidence-based treatment plansResistance profilesMajor global health concernRapid drug susceptibility testingMycobacterium tuberculosis isolatesNext-generation sequencingClinical samplesAmplification of resistanceDrug susceptibility testingTargeted Next-Generation SequencingMycobacterium tuberculosis DNAGlobal health concernSusceptibility testing resultsSame clinical samplePhenotypic DSTInfectious causesTreatment outcomesTuberculosis isolates
2013
Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007.
Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Eurosurveillance 2013, 18 PMID: 24128699, DOI: 10.2807/1560-7917.es2013.18.40.20601.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibiotics, AntitubercularAntitubercular AgentsChildChild, PreschoolDrug Resistance, Multiple, BacterialFemaleFluoroquinolonesHumansInfantInfant, NewbornMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPatient ComplianceProspective StudiesRetrospective StudiesSurveys and QuestionnairesTreatment OutcomeTuberculosis, Multidrug-ResistantUnited KingdomYoung AdultConceptsMultidrug-resistant tuberculosisTreatment outcomesRetrospective-prospective cohort studyWorld Health Organization targetMulti-drug resistant tuberculosisMDR-TB patientsMDR-TB treatmentMDR-TB casesFurther drug resistanceTreatment completion ratesSuccessful treatment outcomeUnited Kingdom guidelinesIndividualised regimensCohort studyMonths treatmentResistant tuberculosisTreatment completionInfectious casesDrug resistanceDrug sensitivitySuccessful outcomeOrganization targetBacteriostatic drugsOutcomesTreatment
2012
Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 812-6. PMID: 22507372, PMCID: PMC3786434, DOI: 10.5588/ijtld.11.0637.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsChi-Square DistributionDrug Resistance, BacterialDrug Therapy, CombinationEthambutolFemaleGeorgia (Republic)HumansIsoniazidLogistic ModelsMaleMicrobial Sensitivity TestsMiddle AgedMultivariate AnalysisMycobacterium tuberculosisPredictive Value of TestsPyrazinamideRetrospective StudiesRifampinRisk AssessmentRisk FactorsSputumTime FactorsTreatment OutcomeTuberculosisConceptsPulmonary tuberculosisPrevious treatmentOutcomes of patientsPulmonary TB patientsSubset of patientsRetrospective record reviewForms of tuberculosisFirst-line drugsHigh TB ratesDrug-resistant formsLower ratesLow tuberculosisTB patientsTuberculosis patientsOptimal management strategyTreatment regimenRecord reviewTB ratesTreatment successTreatment outcomesCountry of GeorgiaPatientsIsoniazid resistanceTuberculosisDrug resistance
2010
Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study
Cohen T, Hedt BL, Pagano M. Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study. BMC Public Health 2010, 10: 355. PMID: 20565947, PMCID: PMC2898828, DOI: 10.1186/1471-2458-10-355.Peer-Reviewed Original Research